There are 2 stages in the study. The first stage dose-escalation tests different doses of the study drug. At the beginning of the study, participants will receive a low dose of the drug. If it is well tolerated, the dose will be slowly increased as new people join the study.
In the second stage of the study, participants will receive the maximum tolerated dose determined in the first stage. Participants will receive up to 8 cycles of treatment as long as they do not experience unacceptable side effects and their myeloma does not get worse. Participants who receive 8 cycles of study therapy may be eligible to receive additional cycles of DFRFA for up to 1 year if the study physician determines it is appropriate for them. Click below to view Dr. The purpose of the study is to determine whether adding MLN to the combination of lenalidomide and dexamethasone improves survival in people with relapsed or refractory multiple myeloma.
Lenalidomide and dexamethasone given in combination is approved by the FDA for treating people with myeloma who have received at least one prior therapy.
This story is provided and presented by our sponsor: NewYork-Presbyterian Hospital. Facebook Twitter Email. Is there a cure for multiple myeloma? This story is provided by our sponsor, NewYork-Presbyterian Hospital. The Journal News. Share your feedback to help improve our site!
When you have a rare cancer like multiple myeloma, you need the experience and expertise of a cancer center that is backed by cutting-edge research and that offers a multidisciplinary approach to care. At Columbia Cancer, our highly experienced cancer care team is ready to go to work helping you navigate every step of your cancer journey. At Columbia Cancer, our caregivers see many people with multiple myeloma.
This is a rare disease that has fewer than 4, people in the tristate region diagnosed each year. In addition to offering standard treatment therapies for multiple myeloma and other plasma cell disorders, we offer access to the most promising new drugs and medical procedures through clinical trials.
These trials allow us to bring new therapeutic options to our patients, often years before they become widely available.
We are committed to moving the field forward through medical advances with the potential to alleviate the suffering from myeloma in the future. Our ultimate goal is to find a cure for multiple myeloma. In concert with your referring physician, we are always available to offer a second opinion in the form of a consultation with one of our specialists.
We have the latest knowledge, expertise and experience, and we put our patients at the center of everything that we do. We provide outstanding clinical care in the context of a world-class clinical research program. The team at the Multiple Myeloma Center is dedicated to delivering the most promising diagnostic testing and treatments in a supportive and collaborative environment so that our patients and their families receive the best possible outcomes and quality of life.
We also conduct more studies in blood cancers than any of our regional peers, allowing us to provide our patients with access to many multi-phase clinical trials.
0コメント